{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:41:30Z","timestamp":1766086890263},"reference-count":12,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.clml.2013.10.001","type":"journal-article","created":{"date-parts":[[2013,11,11]],"date-time":"2013-11-11T19:29:25Z","timestamp":1384198165000},"page":"172-177.e1","source":"Crossref","is-referenced-by-count":4,"title":["Ribosomal S6 Kinase and AKT Phosphorylation as Pharmacodynamic Biomarkers in Patients With Myelodysplastic Syndrome Treated With RAD001"],"prefix":"10.1016","volume":"14","author":[{"given":"Anjali S.","family":"Advani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reda Z.","family":"Mahfouz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslaw","family":"Maciejewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Rybicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikkael","family":"Sekeres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Tripp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt","family":"Kalaycio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Bates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogen","family":"Saunthararajah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2013.10.001_bib1","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of MTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Genes and Development"},{"key":"10.1016\/j.clml.2013.10.001_bib2","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for\u00a0evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.10.001_bib3","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized control trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.10.001_bib4","first-page":"3671","article-title":"Report of an international working group to standardize response criteria for myelodysplastic syndrome","volume":"96","author":"Cheson","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.10.001_bib5","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-06-0764","article-title":"Phase I\/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies","volume":"12","author":"Yee","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2013.10.001_bib6","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/sj.leu.2404245","article-title":"Phosphoinositide 3-kinase\/AKT signaling pathway and its therapeutic implications for human acute myeloid leukemia","volume":"20","author":"Martelli","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.10.001_bib7","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2002-11-3325","article-title":"A\u00a0simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome","volume":"102","author":"Saunthararajah","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.10.001_bib8","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1517\/14728222.2012.677439","article-title":"An overview of the mTOR pathway as a target in cancer therapy","volume":"16","author":"Gentzler","year":"2012","journal-title":"Expert Opin Ther Targets"},{"issue":"suppl 2","key":"10.1016\/j.clml.2013.10.001_bib9","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1038\/onc.2009.352","article-title":"Common corruption of the mTOR signaling network in human tumors","volume":"27","author":"Menon","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2013.10.001_bib10","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.4161\/cc.10.22.18124","article-title":"High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1","volume":"10","author":"Yellen","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.clml.2013.10.001_bib11","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1158\/1078-0432.CCR-11-2346","article-title":"Single-cell pharmacodynamic monitoring of\u00a0S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy","volume":"18","author":"Perl","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2013.10.001_bib12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1535-6108(03)00248-4","article-title":"Targeting the PI3K-AKT pathway in human cancer: rationale and promise","volume":"4","author":"Luo","year":"2003","journal-title":"Cancer Cell"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013004576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013004576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T18:39:59Z","timestamp":1596825599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265013004576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S2152265013004576"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2013.10.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}